Molecular Genomics Core

项目总结 分子基因组学核心(MGC)的总体目标是促进莫菲特癌症中心的研究 (MCC)通过提供最先进的、及时的、具有竞争力的高质量基因组学服务。 MGC有三个具体目标，以教育、咨询和服务为中心。MGC的可持续性 该模型的基础是促进基因组学技术方面的教育，从而培养人们对它们的使用兴趣 回答特定的科学问题。然后，MGC为成员提供免费咨询，以完善实验 设计和支持赠款申请。这些组成部分导致资助的赠款申请进一步推动 需求。MGC有三个目标：1)为成员提供具体的实验设计咨询；2) 向会员提供高质量的分子基因组学服务；3)向会员提供高质量的基因组学教育。 MGC由六名全职工作人员组成，提供以下服务：完整外显子组和靶向DNA 测序，mRNA和小RNA-序列，芯片-序列，定量聚合酶链式反应，桑格测序，细胞系 鉴定、纳米串计数器分析和微阵列服务，包括表达、单核苷酸 使用各种平台的多态(SNPs)、拷贝数变异(CNV)和甲基化阵列。 MGC通过为以下成员开发和提供尖端服务，对MCC产生了重大影响 注重促进精准医疗造福患者。MGC与TC和CIC密切合作 提供样品采集、数据生成和分析的无缝集成。MGC的影响是 MGC支持的包括临床和分子数据在内的顶级出版物的数量就是例证， 例如Koomen博士的免疫球蛋白可变区大规模并行测序的新方法 在多发性骨髓瘤患者中(Remly-Wood，2014)和Eric Padron博士对慢性 分子水平的粒单核细胞白血病队列(Padron，2014)。 为回应先前的检讨，该局对其改善服务的目标作出重大调整。 针对成员，并采用新技术，如靶向和外显子组测序，RNA和芯片- SEQ、纳米串和细胞系认证。因此，MGC的收入比过去增加了293% 资金周期，MGC被所有五个计划的成员大量使用。在最近一个财政年度 去年，MGC为MCC成员提供了服务，同行评议资助的成员使用了88%的资源。

PROJECT SUMMARY The overall goal of the Molecular Genomics Core (MGC) is to facilitate research at the Moffitt Cancer Center (MCC) by providing high-quality genomics services that are state-of-the-art, timely, and competitively priced. The MGC has three specific aims centered on education, consultations, and services. MGC's sustainability model is based on promoting education in technological aspects of genomics, which builds interest in their use to answer specific scientific questions. The MGC then offers members free consultations to refine experimental design and to support grant applications. These components lead to funded grant applications further driving demand. The MGC has three aims, to provide: 1) specific experimental design consultations to members; 2) high-quality molecular genomics services to members; and 3) high-quality genomics education to members. The MGC comprises six full-time staff and provides the following services: whole exome and targeted DNA sequencing, mRNA and small RNA-Seq, ChIP-seq, quantitative PCR, Sanger sequencing, cell line authentication, NanoString nCounter analysis, and microarray services including expression, single nucleotide polymorphisms (SNPs), copy number variants (CNV), and methylation arrays using a variety of platforms. The MGC has a major impact on the MCC by developing and providing cutting-edge services to members with a focus on facilitating precision medicine to benefit patients. The MGC works closely with the TC and the CIC to provide seamless integration of sample acquisition, data generation, and analysis. The impact of the MGC is exemplified by the number of MGC-supported top-tier publications that include clinical and molecular data, such as Dr. Koomen's novel approach of massively parallel sequencing of the immunoglobulin variable regions in multiple myeloma patients (Remily-Wood, 2014) and Dr. Eric Padron's characterization of a chronic myelomonocytic leukemia cohort at the molecular level (Padron, 2014). In response to the prior review, the MGC underwent a significant realignment of its aims to improve services for members and to incorporate new technologies such as targeted and exome sequencing, RNA- and ChIP- Seq, NanoString and cell line authentication. As a result, MGC revenues increased by 293% over the past funding cycle, and the MGC is heavily used by members from all five programs. During the most recent fiscal year, the MGC served 64 MCC members, with 88% of total utilization by peer-review-funded members.